← All trials
NCT06815627
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Feb 28, 2025
- Primary completion
- Feb 28, 2027
- Completion date
- Feb 28, 2027
- First posted
- Feb 7, 2025
- Last posted
- Feb 13, 2025
- Enrollment
- 150
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Trust Bio-sonics, Inc.Lead sponsor
- Chang Gung UniversityOfficial
- Taipei Veteran General hospitalOfficial
- Cathay General HospitalOfficial
- National Taiwan UniversityOfficial
- Mackay Medical CollegeOfficial
- China Medical UniversityOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.